Newsletter | September 10, 2019

09.10.19 -- Spark's 3 Pillars Of Patient Advocacy


Hello Cell & Gene Readers,


Are the methods used for developing the current generation of biopharmaceuticals, monoclonal antibodies, hormone replacements, etc., applicable to the next generation of biotech advanced therapy medicinal products (ATMPs)? When developing and manufacturing cell and gene therapies, do biopharma methods apply?


Patient advocacy plays a tremendously crucial role in the cell and gene sector. Jamie Ring, head of patient advocacy at Spark Therapeutics and a Cell & Gene Editorial Advisory Board member, shared with me valuable information about patient advocacy (e.g. what it is, what it’s not, and the difference between patient advocacy in healthcare overall versus patient advocacy in gene therapy), which we will cover in detail in the coming weeks. To start, Ring lists and explains the three pillars of patient advocacy.


Erin Harris, editor in chief
Follow me on Twitter

Industry Insights
Tube Welders vs. Aseptic Connectors
Article | CPC

Tube welding versus using aseptic connectors — as with any debate, there are strong opinions on both sides. Following are some factors to consider that may tip the scale in favor of aseptic connectors.

Speed Biologics To Clinical Trials Faster
E-Book | GE Healthcare Life Sciences

If your business strategy doesn’t fully align with your organization’s capabilities in terms of expertise, capacity, and resources, it might be wise to consider outsourcing to a biologics CDMO for speed-to-market.

Identifying Heterogeneity Within Rare Cell Populations By Pairing Single-Cell RNA-Seq With Cell Sorting
Application Note | Bio-Rad Laboratories, Inc.

Studying biology at a single-cell level can provide crucial insights into how individual cells contribute to human biology and disease. Here we demonstrate that the resolution of single-cell RNA sequencing (RNA-Seq) can be greatly enhanced by adding a cell-sorting step prior to RNA-Seq analysis.

Connect With Cell & Gene: